Potential new treatment option in ultra-rare, life-threatening, primarily pediatric disease with no approved therapies Lausanne (Switzerland), March 7, 2023 -- AB2 Bio Ltd., a biotechnology company ...
Agreement grants Nippon Shinyaku an option to acquire exclusive U.S. rights to commercialize AB2 Bio’s Tadekinig alfa to treat Primary Monogenic IL-18 driven Hyperinflammatory Syndrome in patients ...
Tadekinig alfa is a novel IL-18 binding protein in pivotal Phase 3 testing for orphan disease IL-18 driven monogenic Hemophagocytic Lymphohistiocytosis (HLH) WuXi Biologics to undertake ...
Japan’s Nippon Shinyaku is continuing to scoop up the international rights to some intriguing drugs, this time penning a $686 million biobucks deal for AB2 Bio’s late-stage autoimmune disease therapy.
Swiss orphan biotech AB2 Bio Ltd. has completed enrollment in a pivotal phase III trial for its recombinant interleukin-18-binding protein drug tadekinig alfa for an inherited form of the ultra-rare ...
Lausanne (Switzerland), March 7, 2023 -- AB2 Bio Ltd., a biotechnology company developing innovative therapies for the treatment of severe systemic autoinflammatory diseases and conditions driven by ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results